Pertussis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 78 pages report, published by Global Markets Direct

Keywords : Pertussis Therapeutic Products under Development, Key Players in Pertussis Therapeutics, Pertussis Pipeline Overview, Pertussis Pipeline, Pertussis Pipeline Assessment

Report ThumbnailSeptember-2013
Pertussis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Pertussis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pertussis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pertussis. Pertussis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pertussis.
- A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pertussis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pertussis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Pertussis, H2 2013 10
  • Products under Development for Pertussis - Comparative Analysis, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • Late Stage Products, H2 2013 15
  • Mid Clinical Stage Products, H2 2013 16
  • Early Clinical Stage Products, H2 2013 17
  • Discovery and Pre-Clinical Stage Products, H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 36
  • Assessment by Combination Products, H2 2013 37
  • Assessment by Route of Administration, H2 2013 38
  • Assessment by Stage and Route of Administration, H2 2013 39
  • Assessment by Molecule Type, H2 2013 40
  • Assessment by Stage and Molecule Type, H2 2013 41
  • List of Tables
  • Number of Products Under Development for Pertussis, H2 2013 10
  • Products under Development for Pertussis - Comparative Analysis, H2 2013 11
  • Number of Products under Development by Companies, H2 2013 13
  • Number of Products under Investigation by Universities/Institutes, H2 2013 14
  • Comparative Analysis by Late Stage Development, H2 2013 15
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 17
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
  • Products under Development by Companies, H2 2013 19
  • Products under Investigation by Universities/Institutes, H2 2013 20
  • Sanofi-Aventis, H2 2013 21
  • GlaxoSmithKline plc, H2 2013 22
  • Takeda Pharmaceutical Company Limited, H2 2013 23
  • Biological E. Limited, H2 2013 24
  • Novartis AG, H2 2013 25
  • Green Cross Corporation, H2 2013 26
  • LG Life Sciences, Ltd, H2 2013 27
  • Panacea Biotec Limited, H2 2013 28
  • Bharat Biotech International Limited, H2 2013 29
  • Sinovac Biotech Co., Ltd., H2 2013 30
  • Beijing Tiantan Biological Products Co., Ltd., H2 2013 31
  • Adeona Pharmaceuticals, Inc., H2 2013 32
  • Serum Institute of India Limited, H2 2013 33
  • Indian Immunologicals Limited, H2 2013 34
  • Beijing Minhai Biotechnology Co., Ltd, H2 2013 35
  • Assessment by Monotherapy Products, H2 2013 36
  • Assessment by Combination Products, H2 2013 37
  • Assessment by Stage and Route of Administration, H2 2013 39
  • Assessment by Stage and Molecule Type, H2 2013 41
  • Pertussis Therapeutics - Drug Profile Updates 67
  • Pertussis Therapeutics - Discontinued Products 70
  • Pertussis Therapeutics - Dormant Products 71
  • Table of Contents
  • Table of Contents 2
  • List of Tables 6
  • List of Figures 7
  • Introduction 8
  • Global Markets Direct Report Coverage 8
  • Pertussis Overview 9
  • Therapeutics Development 10
  • An Overview of Pipeline Products for Pertussis 10
  • Pertussis Therapeutics under Development by Companies 12
  • Pertussis Therapeutics under Investigation by Universities/Institutes 14
  • Late Stage Products 15
  • Comparative Analysis 15
  • Mid Clinical Stage Products 16
  • Comparative Analysis 16
  • Early Clinical Stage Products 17
  • Comparative Analysis 17
  • Discovery and Pre-Clinical Stage Products 18
  • Comparative Analysis 18
  • Pertussis Therapeutics - Products under Development by Companies 19
  • Pertussis Therapeutics - Products under Investigation by Universities/Institutes 20
  • Companies Involved in Pertussis Therapeutics Development 21
  • Sanofi-Aventis 21
  • GlaxoSmithKline plc 22
  • Takeda Pharmaceutical Company Limited 23
  • Biological E. Limited 24
  • Novartis AG 25
  • Green Cross Corporation 26
  • LG Life Sciences, Ltd 27
  • Panacea Biotec Limited 28
  • Bharat Biotech International Limited 29
  • Sinovac Biotech Co., Ltd. 30
  • Beijing Tiantan Biological Products Co., Ltd. 31
  • Adeona Pharmaceuticals, Inc. 32
  • Serum Institute of India Limited 33
  • Indian Immunologicals Limited 34
  • Beijing Minhai Biotechnology Co., Ltd 35
  • Pertussis - Therapeutics Assessment 36
  • Assessment by Monotherapy Products 36
  • Assessment by Combination Products 37
  • Assessment by Route of Administration 38
  • Assessment by Molecule Type 40
  • Drug Profiles 42
  • Act-HIB reconstituted with TRIPACEL - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • GSK-217744 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • DTP-HepB-Polio-Hib - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • DTaP-HepB - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • DtwP-HB-Hib (liq) Vaccine - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • LBVF-0101 - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • DTwP-HepB Vaccine - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • TAK-361S - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • component pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • SYN-005 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • Acellular Pertussis Vaccine - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • DTwP-HBV-Hib - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • GC-3111A - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • DTwP-IPV - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • Acellular Pertussis Vaccine - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • LBVP-0101 - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • Humanized Antibody Against Pertussis - Drug Profile 61
  • Product Description 61
  • Mechanism of Action 61
  • R&D Progress 61
  • DTaP Vaccine - Drug Profile 62
  • Product Description 62
  • Mechanism of Action 62
  • R&D Progress 62
  • Diphtheria Tetanus Pertussis Low Vaccine - Drug Profile 63
  • Product Description 63
  • Mechanism of Action 63
  • R&D Progress 63
  • Diphtheria Tetanus Acellular Pertussis Vaccine - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • Diphtheria Tetanus Acellular Pertussis Vaccine - Drug Profile 65
  • Product Description 65
  • Mechanism of Action 65
  • R&D Progress 65
  • Pertussis Component Vaccine - Drug Profile 66
  • Product Description 66
  • Mechanism of Action 66
  • R&D Progress 66
  • Pertussis Therapeutics - Drug Profile Updates 67
  • Pertussis Therapeutics - Discontinued Products 70
  • Pertussis Therapeutics - Dormant Products 71
  • Pertussis - Product Development Milestones 72
  • Featured News & Press Releases 72
  • Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 72
  • Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 72
  • Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 73
  • Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 73
  • Jul 08, 2011: GSK Receives FDA Approval For BOOSTRIX To Help Prevent Whooping Cough In Adults 65 Years And Older 74
  • Apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 74
  • Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 75
  • Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 75
  • Jan 30, 2008: GlaxoSmithKline Launches Two New Innovative Vaccines 76
  • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 76
  • Appendix 77
  • Methodology 77
  • Coverage 77
  • Secondary Research 77
  • Primary Research 77
  • Expert Panel Validation 77
  • Contact Us 78
  • Disclaimer 78

Please select a license type

Share

Related Products

Global Markets DirectPertussis - Pipeline Review, H2 2013Product ThumbnailPertussis - Pipeline Review, H2 2013, Industry ReportProduct #: 113286
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved